Related Experiment Video
Updated: Nov 15, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Upstream Statin Therapy and Long-Term Recurrence of Atrial Fibrillation after Cardioversion: A Propensity-Matched
Lukas Fiedler1,2,3, Lára Hallsson2, Maximilian Tscharre1
1Department of Internal Medicine, Cardiology, Nephrology and Intensive Care Medicine, Hospital Wiener Neustadt, 2700 Wiener Neustadt, Austria.
Insights
Statin therapy significantly reduces the long-term risk of atrial fibrillation (AF) recurrence after cardioversion (CV). This study found that patients on statins experienced substantially lower rates of AF returning post-CV.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Conflicting results exist regarding statin therapy's effect on atrial fibrillation (AF) recurrence post-cardioversion (CV).
- Long-term data on statins and AF recurrence after CV is limited.
Purpose of the Study:
- To investigate the association between upstream statin therapy and long-term AF recurrence after CV.
- To evaluate the impact of statins on maintaining sinus rhythm following electrical cardioversion.
Main Methods:
- Single-center registry study of 454 consecutive AF patients undergoing CV.
- Cox regression models and propensity score matching (1:1 ratio) were used to analyze AF recurrence.
- Follow-up median duration was 373 days.
Main Results:
- Statin therapy was associated with a significantly lower rate of AF recurrence (log-rank p < 0.001).
- Adjusted Cox regression showed statins reduced AF recurrence risk (HR 0.238, p < 0.001).
- Propensity score matching revealed a 27.5% absolute risk reduction in recurrent AF for statin users.
Conclusions:
- Statin therapy is linked to a reduced risk of long-term AF recurrence after successful CV.
- Upstream statin use may be a beneficial strategy for maintaining sinus rhythm post-cardioversion.
- Further research could explore mechanisms and optimal statin regimens for AF management.
Abstract:
The relationship of statin therapy with recurrence of atrial fibrillation (AF) after cardioversion (CV) has been evaluated by several investigations, which provided conflicting results and particularly long-term data is scarce. We sought to examine whether upstream statin therapy is associated with long-term recurrence of AF after CV. This was a single-center registry study including consecutive AF patients (n = 454) undergoing CV. Cox regression models were performed to estimate AF recurrence comparing patients with and without statins. In addition, we performed a propensity score matched analysis with a 1:1 ratio. Statins were prescribed to 183 (40.3%) patients. After a median follow-up period of 373 (207-805) days, recurrence of AF was present in 150 (33.0%) patients. Patients receiving statins had a significantly lower rate of AF recurrence (log-rank p < 0.001). In univariate analysis, statin therapy was associated with a significantly reduced rate of AF recurrence (HR 0.333 (95% CI 0.225-0.493), p = 0.001), which remained significant after adjustment (HR 0.238 (95% CI 0.151-0.375), p < 0.001). After propensity score matching treatment with statins resulted in an absolute risk reduction of 27.5% for recurrent AF (21 (18.1%) vs. 53 (45.7%); p < 0.001). Statin therapy was associated with a reduced risk of long-term AF recurrence after successful cardioversion.
Related Concept Videos
Atherosclerosis III: Management
Venous Thrombosis III: Interprofessional Care
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Coronary Syndrome III: Diagnostic Studies
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

